(Q40771507)

23 September 2017

title

Guidelines update: where do the new therapies fit in the management of asthma? NHLBI and WHO Global Initiative for Asthma (English)

1 reference

World Health Organization

23 September 2017

main subject

0 references

asthma

0 references

author name string

Kemp JP

series ordinal

1

1 reference

23 September 2017

language of work or name

1 reference

1 January 2000

1 reference

23 September 2017

1 reference

23 September 2017

volume

59 Suppl 1

1 reference

23 September 2017

page(s)

23-28; discussion 43-5

1 reference

Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland

23 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059001-00004

Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma

21 January 2018

1 reference

12 December 2020

Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma

1 reference

12 December 2020

Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group

1 reference

12 December 2020

National and international guidelines for the diagnosis and treatment of asthma

1 reference

12 December 2020

Comparison of patients' compliance with prescribed oral and inhaled asthma medications

1 reference

12 December 2020

Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist

1 reference

12 December 2020

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

1 reference

12 December 2020

Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group

1 reference

12 December 2020

Preventive pharmacologic therapy among asthmatics: five years after publication of guidelines

1 reference

12 December 2020

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

1 reference

12 December 2020

Treatment of Medicaid patients with asthma: comparison with treatment guidelines using disease-based drug utilization review methodology

1 reference

12 December 2020

Comparison of guidelines and self-management plans in asthma

1 reference

12 December 2020

Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects

1 reference

12 December 2020

Algorithm for the diagnosis and management of asthma: a practice parameter update: Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology,

1 reference

12 December 2020

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

1 reference

12 December 2020

Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Zileuton Study Group

1 reference

12 December 2020

Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group

1 reference

12 December 2020

Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma

1 reference

12 December 2020

Compliance with national asthma management guidelines and specialty care: a health maintenance organization experience

1 reference

12 December 2020

10.2165/00003495-200059001-00004

Identifiers

DOI

0 references

Dimensions Publication ID

1049267032

0 references

1 reference